BID and thyroid gland carcinoma: Moreover, Gunda and colleagues also suggested that BID is one of the genes responsible for the apoptotic effects of lexatumumab, a monoclonal antibody that specifically activates TRAIL-receptor 2, inducing cell death in thyroid cancer cells [68].